About

About Arbele Arbele is a clinical stage biopharmaceutical company developing targeted immunotherapy to treat gastrointestinal cancers including colorectal, gastric, pancreatic, hepatic and esophageal cancers. Cabotamig (ARB202), a CDH17/CD3 bispecific BiTE molecule has shown good safety profiles and demonstrated target engagement with antitumor activities. Subsequent lines of therapeutics are ARB203 BiTE, ARB102 ADC, and ARB011 CAR expect to enter IND and clinical stages in 2024/25. To detect and intercept cancer development and progressions, our diagnostic affiliate has developed companion tissue diagnostics for anti-CDH17 therapies as well as proprietary liquid biopsy immunoassays. The company welcomes strategic licensing partnership to accelerate multicenter clinical studies and business expansion globally. About Arbele Limited Arbele is a clinical stage biopharmaceutical company developing targeted immunotherapy to treat gastrointestinal cancers including colorectal, gastric, pancreatic, hepatic and esophageal cancers. Cabotamig (ARB202), a CDH17/CD3 bispecific BiTE molecule has shown good safety profiles and demonstrated target engagement with antitumor activities. Subsequent lines of therapeutics are ARB203 BiTE, ARB102 ADC, and ARB011 CAR expect to enter IND and clinical stages in 2024/25. To detect and intercept cancer development and progressions, our diagnostic affiliate has developed companion tissue diagnostics for anti-CDH17 therapies as well as proprietary liquid biopsy immunoassays. The company welcomes strategic licensing partnership to accelerate multicenter clinical studies and business expansion globally. Arbele is a CDH17-pioneer biotech company spearheading potential first-in-class/best-in-class immunotherapies (TCE and ADC) to treat pancreatic and advanced colorectal cancers (2L+). To accelerate the clinical development regulatory pathway, TibTech (an associated Medtech company) has established companion diagnostic platforms to test CA17 expression levels for both tissues and blood samples. Strategic partnerships with BioAI Healthcare and IVD companies position us at a leading competitor over other players.